CLINICAL & PIPELINE·Drug Approval
FDA Approves APIL's ATELVIA (Risedronate Sodium) as New Delayed-Release Dosage Form
The FDA approved APIL's NDA022560 for ATELVIA (Risedronate Sodium) as a Type 3 new delayed-release dosage form on October 8, 2010. This strategic approval for the 35MG oral tablet differentiates APIL's product in the market, necessitating ongoing regulatory and supply chain vigilance for this long-lifecycle asset, with updates extending to 2026.
90-Day Activity